IP Library Granted Patent US 10,052,380
Granted Patent B2
US 10,052,380 · App. 15/822,556 · Granted Aug 21, 2018

Lipidated immune response modifier compound compositions, formulations, and methods

Inventor: Paul D. Wightman (St. Paul, MN)
Assignee: 3M Innovative Properties Company
A61K39/39A61K9/0019A61K9/10A61K9/127A61K31/437A61K31/47A61K39/0011A61K39/145A61K47/26C07D471/04C12N7/00A61K2039/54A61K2039/55511A61K2039/55555A61K2039/55572A61K2039/572C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,052,380
App. No.
15/822,556
Granted
Aug 21, 2018
Kind
B2
Abstract

The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.

Claims (9)

1. A method of reducing tumor size by administering the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is administered directly into a localized tumor mass.

3. The method of claim 2 , wherein the tumor size is reduced by 30 to 100%.

4. The method of claim 3 , wherein the tumor size is reduced by 50 to 90%.

5. The method of claim 4 , wherein the tumor size is reduced by 60 to 80%.

6. The method of claim 5 , wherein the tumor size is reduced by 70%.

7. The method of claim 1 , wherein the tumor size is reduced by at least 90%.

8. A method of inducing an immune response in a localized tissue region by administering the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the compound is administered directly into a localized tumor mass.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066430/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2018
From: WIGHTMAN, PAUL D.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 045490/0064 →
Continuity (5)
Continuation 15241166 · Aug 19, 2016
Continuation 14969483 · Dec 15, 2015
Division 13817214
Provisional Application 61374512 · Aug 17, 2010
Related Publication 20180200364A1 · Jul 19, 2018